Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

l rate of 51 percent. Subset analyses suggested the greatest benefit occurred in the difficult-to-treat patients with prior myelodysplastic syndrome (MDS) or those that had received prior hypomethylating therapy (HMA). Adverse events were mild, predictable and manageable.

About Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Approximately 14,590 new cases of AML were expected to be diagnosed in the United States in 2013.1 As of January 2008 an estimated 30,993 people were living with (or were in remission from) AML.2 Although AML can occur at any age, adults aged 60 years and older are more likely to develop the disease than younger people. AML is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML may develop from the progression of other diseases such as myelodysplastic syndrome (MDS), a blood cancer that also affects the bone marrow leading to a decrease in circulating red blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells leading to infections and bleeding. AML progresses rapidly and is typically fatal within weeks or months if left untreated. Although a substantial proportion of younger individuals who develop AML can be cured, AML in the elderly typically responds poorly to standard therapy with few complete remissions.

About CTI
Cell Therapeutics, Inc. (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to si
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CITY, Calif., Oct. 21, 2014 Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... Second quarter overview: , Revenues of ... , Diluted EPS of $0.24, up 33% over ... , Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, ... today announced they have entered into a license ... designed to target cancers. PhosImmune possesses ... on the surfaces of tumor cells in association ... derived from proteins that play a role in ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... Scientists at Osel Inc . and the ... way to prevent HIV infection by genetically enhancing the ... transmission. Bioengineered bacteria introduced into the vaginal cavity of ... HIV (SHIV) by nearly two thirds. The ...
... NEW YORK, July 18, 2011 NeoStem, Inc., (NYSE-Amex: ... and sell shares of its common stock and warrants in an ... offering will be sold by NeoStem. The offering is subject to ... or when the offering may be completed, or as to the ...
Cached Medicine Technology:Scientists Use Live Bacteria to Fight HIV 2Scientists Use Live Bacteria to Fight HIV 3NeoStem Announces Proposed Public Offering of Common Stock 2NeoStem Announces Proposed Public Offering of Common Stock 3
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... of world,s biological manufacturing capacity is in Puerto Rico, ... the world,s,biotechnology manufacturing capacity is located in Puerto Rico, ... Over the past four years, more than $4 ... such giants as Eli Lilly, Amgen, Abbot,Ortho Biologics, BD ...
... jobs that require them to be physically active may be ... be at a decreased risk of developing prostate cancer, according ... studied more than 2,100 men who worked at the Rocketdyne ... exposed to radiation and chemicals that may have increased their ...
... Feb. 12 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: ... company,s,business direction in light of the recent decision from ... the FDA, PreMD today filed a request for ... with the following Code of Federal Regulations 21,CFR part ...
... Brings Significant Healthcare Leadership Experience to CTG,s Board, ... ), an,international information technology (IT) staffing and solutions company,today ... McGuire, a,healthcare executive who has served as CEO of ... a Director of CTG. Most recently,Mr. McGuire served from ...
... N.J., Feb. 12 TeamStaff, Inc.,(Nasdaq: ... and administrative,staffing services, announced today that it ... division, RS Staffing Services, Inc., to TeamStaff,Government ... Georgia based subsidiary currently provides medical, office,administration ...
... YUCAIPA, Calif., Feb. 12 Ingen Technologies,Inc. (OTC ... the signed distribution agreement with Progressive International,Holding Co. ... Taiwan, People,s,Republic of China, Japan and Korea. Please ... Progressive International Holding Company (PIHK),( http://www.pgiholding.com ) and ...
Cached Medicine News:Health News:Opportunities to Invest in Puerto Rico as Global Center for Biotechnology 2Health News:Men who are continually active at work may have a decreased risk of prostate cancer 2Health News:Men who are continually active at work may have a decreased risk of prostate cancer 3Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 2Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 3Health News:CTG Names William D. McGuire a Director 2Health News:CTG Names William D. McGuire a Director 3Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 3
... unique microprocessor controlled shaking incubator that accommodates ... or 384 well format. Speed, temperature and ... and all are displayed on the LCD. ... protective cover. The Millennium 2000 can be ...
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
... FACSCalibur is the only four-color, automated ... both analysis and cell sorting. Designed specifically ... the FACSCalibur system offers software instrument control, ... maximum ease and productivity. FACSCalibur is fully ...
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
Medicine Products: